Adoram Therapeutics

Executive Summary

Adoram Therapeutics, a Swiss biotech spin-off from the University of Geneva, leverages allosteric biochemistry to develop novel treatments for solid tumors and immune-based diseases. Founded in 2021, the company focuses on modulating protein function through non-active site binding, offering potential advantages in selectivity and reduced side effects. Its lead program targets a validated oncogenic pathway and has advanced to Phase 3 clinical trials, positioning Adoram as a late-stage player in the precision oncology space. The company's Phase 3 trial is evaluating its lead allosteric inhibitor in patients with a specific solid tumor indication, with topline data expected in the near term. Success could support a regulatory submission in key markets, including the US and EU. Adoram aims to address significant unmet needs in tumors with limited treatment options, leveraging its allosteric platform to achieve durable responses. With a strong scientific foundation and late-stage assets, Adoram represents a compelling opportunity in the biotech landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 topline data readout for lead allosteric inhibitor in solid tumors65% success
• Q1 2027Regulatory submission (NDA/MAA) for lead program in major markets55% success
• Q4 2026Potential strategic partnership or licensing deal for pipeline assets50% success